Fundraising Fox
Kairos Pharma
NYSE: KAPALos Angeles, US · Delaware corporation
Find your way into Kairos Pharma
Sign up to see every warm intro you have to Kairos Pharma
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Kairos Pharma team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Kairos Pharma is a clinical-stage biopharmaceutical company developing therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression. Its pipeline includes ENV105, a CD105 antibody in Phase 2 prostate cancer and Phase 1 lung cancer trials, and immunotherapy candidates KROS101 and KROS201 for oncology indications including glioblastoma.
Founders & leadership
NB
Neil BhowmickChief Scientific Officer
RM
Ramachandran MuraliVice President of Research and Development
DS
Doug SamuelsonChief Financial Officer
Board
HW
Hyun W. BaeIndependent Director
HM
Hansoo Michael KeyoungIndependent Director
RS
Rahul SinghviIndependent Director
Reported raises · per SEC filings
Form D private placements$4.2M disclosed across 2 rounds · 2022–2025
▶$3.5MraisedJan 2025 · 1 investors · PharmaceuticalsRule 506(b)
▶$3.5MraisedJan 2025 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Hyun W. BaeDirector
- Neil BhowmickExecutive Officer
- John S. YuExecutive Officer, Director
- Hansoo Michael KeyoungDirector
- Ramachandran MuraliExecutive Officer
- Doug SamuelsonExecutive Officer
- Rahul SinghviDirector
- Offering amount
- $8.8M
- Amount sold
- $3.5M
- Sales commissions
- $279.8K
- Placement agents
- D. Boral Capital LLC
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$675KraisedApr 2023 · 9 investors · PharmaceuticalsRule 506(b)
▶$675KraisedApr 2023 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- John YuExecutive Officer, Director
- Neil BhowmickExecutive Officer
- Ramachandran MuraliExecutive Officer
- Doug SamuelsonExecutive Officer
- Hyun BaeDirector
- Offering amount
- $3M
- Amount sold
- $675K
- Minimum investment
- $25K
- Sales commissions
- $106.2K
- Placement agents
- Boustead Securities, LLC
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$51.4Mvaluation at IPOSep 2024 · $4.00/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 7
RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
TipRanksFinancial analysis and stock research platform.
PublicPublic is a trading platform that allows users to buy and sell cryptocurrencies including Bitcoin, Ethereum, and memecoins through accounts managed by Zero Hash LLC, a New York State-licensed virtual currency business.
StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.
KrakenKraken 360 Investments provides capital and launch infrastructure to blockchain protocols in pre-token and early post-token phases, offering custody, staking, treasury, and liquidity services alongside fundraising support.
Companies working in the same space as Kairos Pharma.
In the news
Frequently asked questions
- What does Kairos Pharma do?
- Kairos Pharma is a clinical-stage biopharmaceutical company developing therapies to overcome resistance to cancer drugs and reverse cancer-induced immune suppression. Its pipeline includes ENV105, a CD105 antibody in Phase 2 prostate cancer and Phase 1 lung cancer trials, and immunotherapy candidates KROS101 and KROS201 for oncology indications including glioblastoma.
- Who founded Kairos Pharma?
- Kairos Pharma was founded by John S. Yu.
- How much funding has Kairos Pharma raised?
- Kairos Pharma has disclosed $4.2M raised across 2 rounds.
- Where is Kairos Pharma headquartered?
- Kairos Pharma is headquartered in Los Angeles, US.